nafamostat has been researched along with Alloxan Diabetes in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, H | 1 |
| Mashima, Y | 1 |
| Tashiro, T | 1 |
| Yamamori, H | 1 |
| Horibe, K | 1 |
| Nishizawa, M | 1 |
| Okui, K | 1 |
1 other study available for nafamostat and Alloxan Diabetes
| Article | Year |
|---|---|
[Studies on stable control of blood sugar by continuous administration of insulin through isolated intestinal loop].
Topics: Animals; Aprotinin; Benzamidines; Blood Glucose; Catheters, Indwelling; Diabetes Mellitus, Experimen | 1992 |